Twist Bioscience/$TWST
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Twist Bioscience
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well-plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies and powers cost-effective, rapid high-throughput synthesis, enabling researchers to realize opportunities ahead rapidly. Geographically, it derives a majority of its revenue from the United States.
Ticker
$TWST
Sector
Primary listing
Employees
923
Headquarters
Website
Twist Bioscience Metrics
BasicAdvanced
$1.5B
-
-$1.44
2.37
-
Price and volume
Market cap
$1.5B
Beta
2.37
52-week high
$55.33
52-week low
$24.07
Average daily volume
1.8M
Financial strength
Current ratio
3.902
Quick ratio
3.453
Long term debt to equity
16.238
Total debt to equity
19.479
Interest coverage (TTM)
-4,909.24%
Profitability
EBITDA (TTM)
-119.463
Gross margin (TTM)
49.24%
Net profit margin (TTM)
-23.51%
Operating margin (TTM)
-39.30%
Effective tax rate (TTM)
-0.43%
Revenue per employee (TTM)
$390,000
Management effectiveness
Return on assets (TTM)
-13.88%
Return on equity (TTM)
-17.58%
Valuation
Price to revenue (TTM)
4.147
Price to book
3.18
Price to tangible book (TTM)
3.18
Price to free cash flow (TTM)
-21.865
Free cash flow yield (TTM)
-4.57%
Free cash flow per share (TTM)
-1.158
Growth
Revenue change (TTM)
22.72%
Earnings per share change (TTM)
-62.34%
3-year revenue growth (CAGR)
25.29%
3-year earnings per share growth (CAGR)
-28.84%
What the Analysts think about Twist Bioscience
Analyst ratings (Buy, Hold, Sell) for Twist Bioscience stock.
Bulls say / Bears say
Twist delivered record Q3 FY25 revenue of $96.1 million, an 18% year-over-year increase and marking its tenth consecutive quarter of sequential growth. (SEC)
The spin-out of its DNA data storage business into Atlas Data Storage secured $155 million in seed financing, unlocking shareholder value and allowing Twist to concentrate on core synthetic biology and NGS operations. (SEC)
Twist’s proprietary silicon-based DNA synthesis platform uses 99.8% less reagents than traditional 96-well plate methods, significantly reducing carbon emissions and strengthening its ESG profile. (FT)
As of December 31, 2024, Twist had an accumulated net deficit of $1.27 billion, underscoring persistent unprofitability despite top-line growth. (SEC)
Twist projects an adjusted EBITDA loss of $45 million to $47 million for fiscal 2025, indicating it will remain unprofitable at least through the year and defer breakeven until fiscal 2026. (SEC)
Growth in the core synthetic biology segment slowed to just 7% year-over-year in Q3 FY25, lagging behind its NGS business and suggesting potential market saturation. (SEC)
Data summarised monthly by Lightyear AI. Last updated on 3 Sept 2025.
Twist Bioscience Financial Performance
Revenues and expenses
Twist Bioscience Earnings Performance
Company profitability
Twist Bioscience News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Twist Bioscience stock?
Twist Bioscience (TWST) has a market cap of $1.5B as of September 15, 2025.
What is the P/E ratio for Twist Bioscience stock?
The price to earnings (P/E) ratio for Twist Bioscience (TWST) stock is 0 as of September 15, 2025.
Does Twist Bioscience stock pay dividends?
No, Twist Bioscience (TWST) stock does not pay dividends to its shareholders as of September 15, 2025.
When is the next Twist Bioscience dividend payment date?
Twist Bioscience (TWST) stock does not pay dividends to its shareholders.
What is the beta indicator for Twist Bioscience?
Twist Bioscience (TWST) has a beta rating of 2.37. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.